Hodnota podniku společnosti QSAM Biosciences

Jaká je hodnota metriky Hodnota podniku společnosti QSAM Biosciences?

Hodnota metriky Hodnota podniku společnosti QSAM Biosciences, Inc. je $10.28M

Jaká je definice metriky Hodnota podniku?

Podniková hodnota (Enterprise value) je měřítkem celkové tržní hodnoty společnosti. Vypočítává se jako tržní kapitalizace s dluhem, menšinovým podílem a přednostními akciemi sníženými o celkovou hodnotu dostupných peněz a jejich ekvivalentů.

It is a sum of claims by all claimants including creditors (secured and unsecured) and shareholders (preferred and common). Enterprise value is one of the fundamental metrics used in business valuation, financial modeling, accounting, portfolio analysis, and risk analysis. Enterprise value is more comprehensive than market capitalization, which only reflects common equity and is considered more representative of a company’s value. Enterprise value reflects the opportunistic nature of business and may change substantially over time because of both external and internal conditions.

Enterprise value can be negative if the company holds abnormally high amounts of cash that is not reflected in the market value of the stock and total capitalization. Cash is subtracted in the calculation because it reduces the net cost to a potential purchaser. The effect applies whether the cash is used to issue dividends or to pay down debt. Value of minority interest is added because it reflects the claim on assets consolidated into the firm in question. Value of associate companies is subtracted because it reflects the claim on assets consolidated into other firms. EV should also include such special components as unfunded pension liabilities, employee stock options, environmental provisions, abandonment provisions, and so on, since they also reflect claims on the company.

Čemu se věnuje společnost QSAM Biosciences?

QSAM Biosciences, Inc., a clinical stage biotechnology company, develops drugs for the treatment of bone cancer. The company is involved in the development of CycloSam (Samaium-153 DOTMP), a clinical-stage novel radiopharmaceutical for the treatment of bone cancer and related diseases. It has a license agreement with IGL Pharma, Inc. The company was formerly known as Q2Earth, Inc. and changed its name to QSAM Biosciences, Inc. in September 2020. QSAM Biosciences, Inc. was founded in 2004 and is based in Austin, Texas.

Firmy s metrikou hodnota podniku podobnou společnosti QSAM Biosciences